s_150203_3a
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- YAP1_MAMLD1
- e1_e2
- E2
- umap1_2d
- -7.321029207
- umap2_2d
- 1.43211766
- umap1_3d
- -0.43112445
- umap2_3d
- 3.733769581
- umap3_3d
- 1.388815621
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- TGF_BETA_SIGNALING+0.240
- MITOTIC_SPINDLE+0.220
- INTERFERON_ALPHA_RESPONSE+0.200
- ANGIOGENESIS+0.190
- UV_RESPONSE_DN+0.180
- COAGULATION+0.140
- INTERFERON_GAMMA_RESPONSE+0.130
- G2M_CHECKPOINT+0.120
- WNT_BETA_CATENIN_SIGNALING+0.120
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.530
- MTORC1_SIGNALING-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- FATTY_ACID_METABOLISM-0.370
- ADIPOGENESIS-0.360
- MYC_TARGETS_V1-0.340
- BILE_ACID_METABOLISM-0.320
- PEROXISOME-0.310
- XENOBIOTIC_METABOLISM-0.310
- PROTEIN_SECRETION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-93-A4JN-01A-11R-A24X-07 | — | cohortA1 | 0.794 |
| 2 | BS_C41DJZ1F | high-grade glioma | — | 0.779 |
| 3 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.765 |
| 4 | 156a3def-5866-4be4-ad0b-61b957d5b6eb | — | — | 0.762 |
| 5 | 2d85d8b8-a590-4a3a-96f2-3f44b5a77032 | — | — | 0.762 |
| 6 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.761 |
| 7 | SRR4195659 | — | — | 0.751 |
| 8 | SRR27320698 | — | — | 0.744 |
| 9 | SRR8526728 | — | cohortSQ1 | 0.741 |
| 10 | MNG55 | — | — | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |